SDMA is a marker of detrimental outcome in the acute phase after ischemic stroke: Role of renal function
Overview & Synopsis
Methylarginines have been shown to interfere with nitric oxide (NO) formation by inhibiting NO synthase (asymmetric dimethylarginine, ADMA) and cellular L-arginine uptake into the cell (ADMA, and symmetric dimethylarginine, SDMA). In a recent study elevation of SDMA was related to long term mortality in patient recruited 30 days after a stroke event. In the present study we aimed to investigate the association of SDMA and adverse clinical outcome in the early phase (first 30 days) after acute ischemic stroke. 137 patients were recruited immediately upon admission to the emergency unit with an acute ischemic stroke. Plasma levels of methylarginines were determined by a validated LC/MS-MS method. Patients were prospectively followed for 30 days. 25 patients (18.2 %) experienced the primary composite endpoint (death, recurrent stroke, MI, rehospitalisation). SDMA plasma levels were significantly higher in patients with compared to patients without event (0.89±0.80 vs. 0.51±0.24 µmol/l; p
hal.science)
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | SDMA is a marker of detrimental outcome in the acute phase after ischemic stroke: Role of renal function |
|---|---|
| Author / Organization | Nicole Lüneburg, Rouven Alexander von Holten, Rudolf F Töpper, Edzard Schwedhelm, Renke Maas, Rainer H Böger |
| Subject & Discipline | Multidisciplinary Academic Open Research |
| Categories | Science & Mathematics |
| Publication Year | 2011 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
HAL Open Science
(hal.science)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-25073 |
| Original Source Link | Visit Source Page on hal.science » |